Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.
Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, Silberberg Y, Atarashi K, Furuichi M, Oka A, Liu B, Fibelman M, Weiner IN, Khabra E, Cullin N, Ben-Yishai N, Inbar D, Ben-David H, Nicenboim J, Kowalsman N, Lieb W, Kario E, Cohen T, Geffen YF, Zelcbuch L, Cohen A, Rappo U, Gahali-Sass I, Golembo M, Lev V, Dori-Bachash M, Shapiro H, Moresi C, Cuevas-Sierra A, Mohapatra G, Kern L, Zheng D, Nobs SP, Suez J, Stettner N, Harmelin A, Zak N, Puttagunta S, Bassan M, Honda K, Sokol H, Bang C, Franke A, Schramm C, Maharshak N, Sartor RB, Sorek R, Elinav E. Federici S, et al. Among authors: rappo u. Cell. 2022 Aug 4;185(16):2879-2898.e24. doi: 10.1016/j.cell.2022.07.003. Epub 2022 Aug 4. Cell. 2022. PMID: 35931020 Free article.
Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial.
Golembo M, Puttagunta S, Rappo U, Weinstock E, Engelstein R, Gahali-Sass I, Moses A, Kario E, Ben-Dor Cohen E, Nicenboim J, Ben David H, Sudakov K, Cohen A, Bassan M, Zak NB. Golembo M, et al. Among authors: rappo u. Skin Health Dis. 2022 Jan 28;2(2):e93. doi: 10.1002/ski2.93. eCollection 2022 Jun. Skin Health Dis. 2022. PMID: 35677920 Free PMC article.
Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Gonzalez PL, Rappo U, Mas Casullo V, Akinapelli K, McGregor JS, Nelson J, Nowak M, Puttagunta S, Dunne MW. Gonzalez PL, et al. Among authors: rappo u. Infect Dis Ther. 2021 Mar;10(1):471-481. doi: 10.1007/s40121-021-00402-0. Epub 2021 Jan 30. Infect Dis Ther. 2021. PMID: 33515414 Free PMC article.
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Turner NA, et al. Among authors: rappo u. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. Trials. 2022. PMID: 35578360 Free PMC article.
15 results